Research Archives – Treatment Action Group

Research Toward a Cure Trials

July 15, 2022
Dorrit Walsh

A listing of clinical trials and observational studies related to the research effort to cure HIV infection, mainly derived from the clinicaltrials.gov online registry. Click the trial registry identifier numbers for a link to the full entry containing detailed information on the trial design, enrollment criteria, principal investigators and location(s).

European Commitments to TB R&D Investments: Promises Made to Be Broken?

February 18, 2022
Dorrit Walsh

In this brief, TAG outlines the pathway the EU can take to scale up support for TB R&D, and advance the many European-sponsored TB vaccine candidates currently in the development pipeline.

Update on HIV Vaccine Research

November 11, 2021
Dorrit Walsh

Developing an HIV vaccine is a difficult scientific challenge, but remains a critical priority. This handout provides an update on HIV vaccine research and a summary of results from the efficacy trials that have been conducted to date, and it…

HIV Research Advocacy Fact Sheet

October 26, 2021
Dorrit Walsh

HIV advocacy laid the foundation for much of the work we do today. This handout was developed in collaboration with the Black AIDS Institute, HIV Vaccine Trials Network, and Southern AIDS Coalition. The handout provides a summary of the history…

New HIV Prevention Research Fact Sheet

October 26, 2021
Dorrit Walsh

HIV prevention research continues to rapidly evolve. The availability of pre-exposure prophylaxis (PrEP) has necessitated the development of new approaches to testing the efficacy of additional biomedical HIV prevention options. This handout was developed in collaboration with the Black AIDS…

Broadly Neutralizing Antibodies for HIV Prevention Fact Sheet

October 26, 2021
Dorrit Walsh

HIV-specific broadly neutralizing antibodies (bNAbs) could have a role in treating, preventing, or even curing HIV. Some HIV-specific bNAbs are already being tested in clinical trials, both for prevention and treatment. This handout was developed in collaboration with the Black…

Substantial Public Investments in GeneXpert Underscore Need for Affordable Pricing

August 27, 2021
Dorrit Walsh

TAG’s comprehensive analysis found that the public invested at least $252 million USD in the research and development of GeneXpert diagnostic technology, which stands in stark contrast to the lack of affordable pricing and favorable service and maintenance terms from the diagnostics company Cepheid.

Comments to NIH Leadership Regarding the Proposed Advanced Research Projects Agency for Health

August 5, 2021
Dorrit Walsh

In response to the Biden administration's intention to create a new research agency under the NIH called the Advanced Research Projects Agency for Health (ARPA-H), TAG and AVAC were invited to present remarks and guidance on the behalf of the Federal AIDS Policy Partnership and Research Work Group (RWG).

Investment in HIV Research Profoundly Benefits the COVID-19 Response

December 2, 2020
Dorrit Walsh

This policy brief discusses how investment in HIV research has profoundly benefitted the COVID-19 response, and advocates that continued financial support for HIV science can both ensure progress on COVID-19 and avoid losing ground—and lives—in the fight to end the HIV epidemic.

Treatment Action Group Statement on New HIV Remission Case Report at AIDS2020

July 8, 2020
Dorrit Walsh

Yesterday, a widely reported presentation by Ricardo Diaz at the ongoing virtual International AIDS Conference (AIDS2020) disclosed that one out of 30 total participants in an HIV cure-related research trial conducted in Brazil has not experienced an HIV viral load rebound for a little over a year (64.7 weeks) after interrupting antiretroviral therapy (ART).